Introduction
Triple negative breast cancer (TNBC) is defined based on the lack of the expression of the estrogen (ERα) and progesterone (PR) receptors, as well as the absence of HER2 amplification. As this is a diagnosis of exclusion, TNBC is a highly heterogeneous subgroup of breast cancer with poor outcome. While numerous studies have aimed to further stratify TNBC in order to tailor treatment (reviewed in Bianchini and colleagues) 1 , to date these have not resulted in a change in standard of care (SoC); most patients receive DNA-damaging chemotherapy ± taxanes in the adjuvant and, more recently, the neoadjuvant setting. 2, 3 While some patients respond very well to this treatment regimen, there is still a significant proportion of patients who receive little clinical benefit, relapse and die from their disease in a short period of time. 4 Therefore, there is a significant unmet clinical need to identify biomarkers that allow TNBC to be stratified based on knowledge of the underlying biology and for treatment options to be tailored accordingly.
We and others have shown that the prolyl isomerase, Pin1, is transcriptionally repressed by BRCA1. 5, 6 Furthermore, we have shown that high Pin1 levels, as observed in the absence of functional BRCA1, results in increased activity of the Src family kinase, Lyn. 5 This leads to increased migration and invasion, key features of aggressive breast cancer. Given the strong link between BRCA1 dysfunction (BRCAness) and TNBC, 7 as well as association of Pin1 with poor prognostic factors such as high grade, 8 we thought it pertinent to investigate the role of Pin1 in TNBC and the potential therapeutic implications.
Materials and methods

Cell lines
All cell lines have been described before, 9 with the exception of the HCC3153 cells which were obtained from Adi Gazdar (UT Southwestern, Dallas, TX, USA). Cell lines were characterized by isoenzyme/cytochrome c oxidase I (COI) assay and short tandem repeat (STR) analysis by ATCC.
Growth assays and dose response curves
Cells were pretreated with short interfering RNA (siRNA) for 24 h before reseeding at an optimized cell density. For growth assays, cells were stained with crystal violet and quantified at an absorbance of 570 nm following reabsorption with sodium citrate. For dose response curves, cells were treated with (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT; Sigma, St. Louis, MO, USA) for 3-4 h, 72 h post drug treatment. Crystals were reabsorbed with DMSO and quantified at an absorbance of 570 nm. All chemotherapies were obtained from the Belfast City Hospital Pharmacy. UMI-77 was purchased from Cayman Chemicals (Ann Arbor, MI, USA) and Olaparib was purchased from Axon MedChem (Groningen, The Netherlands).
Short interfering RNA
Transfections were done using RNAiMax reagent (Invitrogen, UK), as outlined in the manufacturer's instructions. siRNA oligonucleotides were obtained from Eurofins and used at a final concentration of 10 nM. Scr: AAGCAGCACGACT TCTTCAAG and Pin1: CTGGCCTCACAGTT CAGCG and GCTCAGGCCGAGTGTACTA Only cores with identifiable tumour as confirmed by pathology assessment of H&E slides were used in IHC analysis. All IHC was scored independently by at least two experienced immunohistochemists blinded to patient clinicopathological and outcome data.
Western blot analysis
Survival analysis and statistics
All survival analysis (Relapse and Overall) and statistical analysis was carried out using GraphPad Prism (v8.2).
Results
We first investigated Pin1 expression using a publicly available RNASeq dataset of 77 breast cancer cell lines. Next, we wanted to investigate the role of Pin1 in response to chemotherapy, as Pin1 has been linked to drug resistance and chemotherapy is SoC for TNBC. 15 We first examined the effect of Pin1 knockdown on the cellular response to the antimicrotubule agent Taxol (Paclitaxel) using dose response curves. While no difference was observed in BRCA1-proficient cell lines ( Figure 3a , Supplementary Figure S2a and Supplementary Table S2a ), loss of Pin1 expression was associated with a significant increase (~10 fold) in sensitivity to Taxol in the BRCA1 mutant HCC-1937 and Sum149 cell lines (Figure 3b ). In order to investigate this further, the isogenic MDA-468 cell line, where wildtype BRCA1 is overexpressed in the BRCA1-low MDA-468 cell line, was utilized. 14 resistance to treatment (Figure 3d) . In order to test this hypothesis further, we utilized the Mcl-1 inhibitor, UMI-77, 19 and showed a ninefold increase in sensitivity to Taxol in the MDA468 EV cells line compared with that observed with Pin1 siRNA (Figure 3e and Supplementary Table S2c) .
We next wanted to investigate the role of Pin1 in the response to DNA-damaging chemotherapy utilizing an FEC-like cocktail, FEM, to mimic SoC Table  S3b ). In fact, an overall decrease in CtIP levels Figure 2c (ii)], indicating that there may be multiple mechanisms underpinning the modulation of DNA repair by Pin1.
Given the role of Pin1 in multiple cancer-associated phenotypes, we next wanted to investigate whether Pin1 expression could be used as a biomarker to predict outcome in patients with TNBC. Previous published data showed that Pin1 was associated with high grade and poor prognosis breast cancer. 8, 22, 23 This was recapitulated in the analysis of a largely untreated TNBC cohort, 24 showing that high Pin1 mRNA was significantly associated with decreased relapse-free survival [hazard ratio (HR) 1.7; 95% confidence interval (CI) 1.26-2.3; Figure 5A (i) and Supplementary  Table S4A ]. However, given the role of Pin1 in DNA repair, we hypothesized that Pin1 may play an alternative role as a predictive biomarker to DNA-damaging chemotherapy. Indeed, analysis of an FEC-treated TNBC cohort showed that high Pin1 mRNA expression was associated with improved relapse free survival, 9 although this did not quite reach significance (p = 0.0747) [ Figure  5A (ii) and Supplementary Table S4A ]. To explore this further, we carried out Pin1 IHC on two independent TNBC cohorts, both treated with SoC chemotherapy. A range of expression of Pin1 was observed scored as absent (0), low (1), intermediate (2), high (3) and extremely high (4) expression (Figure 5b ). When present, Pin1 was expressed in both the cytoplasm and the nucleus, consistent with its known patterns of localization. 25 Pin1 expression was then correlated with relapse-free and overall survival. Based on preliminary investigations, patients were stratified based on low (Score 0 and 1) and high (Score 2-4) Pin1 expression. Consistent with the gene expression data, high Pin1 was significantly associated with improved relapse-free and overall survival in both the Northern Ireland and Breast Cancer Now Biobank cohorts of patients treated with SoC DNA Damaging chemotherapy (Figure 5c and d and Supplementary Table  S4B ). This appeared to be TNBC specific, as analysis of a larger cohort of FEC-treated breast cancer cases representing all molecular subgroups of breast cancer showed no differences on survival based on Pin1 expression in Luminal (ER+) or HER2+ disease ( Figure 5E and Supplementary Table S4C ). 11
Discussion
In this study we have shown that Pin1 is highly expressed in a subset of TNBC and plays an important role in pathogenesis and response to treatment. We show that knockdown of Pin1 in TNBC cell lines results in cell death, while increased proliferation is observed in normal breast cell lines. Pin1 functions as a differential modulator of chemotherapy response with both BRCA1-depdendent and independent roles. In the context of the antimicrotubule agent Taxol, knockdown of Pin1 results in increased sensitivity but only in the absence of functional BRCA1. We suggest this is mediated through Pin1-dependent stabilization of Mcl-1. Conversely, knockdown of Pin1 results in decreased sensitivity to DNAdamaging chemotherapy. This is observed in both BRCA1 proficient and deficient cell lines. This translates to a potential role for Pin1 as a biomarker to predict response to DNA damaging chemotherapy, which is SoC for TNBC ( Figure 6 ).
Pin1 has been shown to be essential for breast development and plays an oncogenic role in a number of cancer types including breast cancer. 15, 26 Pin1 functions as a prolyl isomerase, catalysing the cis-trans isomerization of proline residues found within pSer/Thr-Pro motifs. This Pin1-dependent isomerization regulates the conformation, and thus the function, of many key proteins, which impacts on many cellular pathways implicated in cancer, including ER-α, NFκB, Stat3, β-catenin, CyclinD1, AKT and Notch. 27 This highlights the potential of Pin1 as a target for therapy. This is further supported by the differential effect of loss of Pin1 expression in cancer versus normal cells observed in our study, indicating cancer specificity. However, the increase in cell proliferation observed in normal cells also supports the potential role of Pin1 as a 'conditional tumour suppressor' as loss of Pin1 is associated with increased expression of cell cycle proteins (e.g. Cyclin E and D) and oncogenes (e.g. MYC) in specific genetic backgrounds. 28 Together with our result, this highlights the continuing need to understand the function of Pin1 in health and disease.
While a number of previous studies have shown that inhibition of Pin1 can sensitize cells to various chemotherapies, [29] [30] [31] [32] this is the first time that Pin1 has been shown to differentially modulate the response to Taxanes and DNA-damaging chemotherapy in a BRCA1 dependent and independent manner, respectively. It is important to note that while Taxanes primarily function through inhibiting mitosis, DNA damage may also be caused as a consequence of mitotic catastrophe. Therefore, these differential effects may not be simply attributed to the primary mechanism of action of these drugs but may also be influenced by differential Pin1 isomerization of proteins involved in drug metabolism, export or DNA damage specific to each drug type.
Our results support the findings of Ding and colleagues, who also demonstrated that Mcl-1 plays a crucial role downstream of Pin1 in resistance to Taxol. 32 However, the BRCA1-dependent phenotype was not described. This indicates that this may be TNBC specific as the cells used in the previous study were either ER+ (MCF-7) or since shown to orginate from melanoma (MDA-MB-435). 33 This supports the tissue-specific role of BRCA1 as recently highlighted by Jonsson and colleagues. 34 Our results indicate a novel therapeutic strategy to resensitize BRCA1 mutant/dysfunction TNBC tumours to Taxol using either direct inhibitors of Mcl-1 or potentially indirect regulators such as Sorafenib as suggested by Ding and colleagues. 32 In contrast, the CtIP-dependent mechanism underpinning the BRCA1-independent role of Pin1 in conferring sensitivity to DNA damaging agents reported by Steger and colleagues could not be recapitulated in our breast cell lines. 20 This further highlights the context specific role of Pin1, whereby it differentially modulates the response to different cellular stresses. This is supported by the recent publication from the Morris laboratory demonstrating that, in the context of replication stress, Pin1 enhances the interaction between BRCA1-BARD1 and RAD51, increasing the presence of RAD51 at stalled replication forks and therefore promoting fork protection. 35 Our findings also highlight the fact that Pin1 may modulate the same response through different mechanisms in different cancer types. Unravelling the exact mechanism by which Pin1 regulates response to DNA damaging agents was beyond the scope of the current project, but through preliminary analysis of a phosphokinase array used to identify key pathways regulated by Pin1, 5 we have identified and validated the DNA repair protein CHK2 as a novel Pin1 target gene (Supplementary Figure S4A) . Knockdown of Pin1 results in loss of phosphorylation of tyrosine 68, a key site in the activation of the kinase, indicating this may be a mechanism of resistance that warrants further investigation. Regardless of the mechanism by which Pin1 regulates response to DNA-damaging chemotherapy, this study highlights the novel potential role of Pin1 as a biomarker to identify women likely to receive clinical benefit from current SoC chemotherapy regimens such as FEC. Furthermore, preliminary analysis of cell line and patient data indicates this may be extended to Cisplatin and Parp inhibitors, which are key treatment options emerging for the management of TNBC. 4 Using publicly available data, we have shown that Pin1 gene expression negatively correlates with IC 50 concentrations of Cisplatin (Supplementary Figure S4B) and the Parp inhibitor, Rucaparib (Supplementary Figure  S4C) , in TNBC cell lines but not breast cancer cell lines as a whole (Supplementary Table S5A ). 36 We have recapitulated this in vitro, demonstrating that knockdown of Pin1 results in decreased sensitivity to both agents in the MDA-MB-468 cell line (Supplementary Figure S3D and Supplementary  Table S5B ). Furthermore, analysis of TNBC patients treated with Cisplatin shows that Pin1 expression correlates significantly (p < 0.0001) with treatment response quantified using the MillerPayne scale (Supplementary Table S4C ). 37 Based on our own results in the context of SoC, and the preliminary indications in the context of other treatment, this warrants further analysis of the potential role of Pin1 as a prognostic and predictive biomarker in additional patient cohorts.
In conclusion, this study demonstrates the oncogenic role of Pin1 driving treatment response in TNBC. The ability of Pin1 to differentially modulate response to treatment emphasizes its context-specific function and highlights the need for continued investigations into the roles of Pin1 in normal cell function as well as cancer. Finally, we highlight the potential of Pin1 as a novel biomarker for the stratification of TNBC patients for treatment in order to improve the management of this poor outcome cancer.
